Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The checkpoint protein Chfr is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition
Dongmin Kang,
James Chen,
Jim Wong, and
Guowei Fang
Department of Biological Sciences, Stanford University, Stanford, CA 94305
Address correspondence to Guowei Fang, Department of Biological Sciences, Stanford University, 385 Serra Mall, MC-5020, Stanford, CA 94305-5020. Tel.: (650) 725-2762. Fax: (650) 725-5807. E-mail: gwfang{at}stanford.edu
Abstract:
The checkpoint protein Chfr delays entry into mitosis, in thepresence of mitotic stress (Scolnick, D.M., and T.D. Halazonetis.2000. Nature. 406:430435). We show here that Chfr isa ubiquitin ligase, both in vitro and in vivo. When transfectedinto HEK293T cells, MycChfr promotes the formation ofhigh molecular weight ubiquitin conjugates. The ring fingerdomain in Chfr is required for the ligase activity; this domainauto-ubiquitinates, and mutations of conserved residues in thisdomain abolish the ligase activity. Using Xenopus cell-freeextracts, we demonstrated that Chfr delays the entry into mitosisby negatively regulating the activation of the Cdc2 kinase atthe G2M transition. Specifically, the Chfr pathway prolongsthe phosphorylated state of tyrosine 15 in Cdc2. The Chfr-mediatedcell cycle delay requires ubiquitin-dependent protein degradation,because inactivating mutations in Chfr, interference with poly-ubiquitination,and inhibition of proteasomes all abolish this delay in mitoticentry. The direct target of the Chfr pathway is Polo-like kinase1 (Plk1). Ubiquitination of Plk1 by Chfr delays the activationof the Cdc25C phosphatase and the inactivation of the Wee1 kinase,leading to a delay in Cdc2 activation. Thus, the Chfr pathwayrepresents a novel checkpoint pathway that regulates the entryinto mitosis by ubiquitin-dependent proteolysis.
Key Words: Chfr; Cdc2; Plk1; mitosis; ubiquitin protein ligase
The editors suggest the following Related Resources on Science sites:
CHFR Protein Expression Predicts Outcomes to Taxane-Based First Line Therapy in Metastatic NSCLC.
R. N. Pillai, S. A. Brodie, G. L. Sica, Y. Shaojin, G. Li, D. C. Nickleach, L. Yuan, V. A. Varma, D. Bonta, J. G. Herman, et al. (2013)
Clin. Cancer Res.
19, 1603-1611
|Abstract »|Full Text »|PDF »
Curcumin-induced mitotic arrest is characterized by spindle abnormalities, defects in chromosomal congression and DNA damage.
L. M. Blakemore, C. Boes, R. Cordell, and M. M. Manson (2013)
Carcinogenesis
34, 351-360
|Abstract »|Full Text »|PDF »
Dnt1 acts as a mitotic inhibitor of the spindle checkpoint protein dma1 in fission yeast.
Y. Wang, W.-z. Li, A. E. Johnson, Z.-q. Luo, X.-l. Sun, A. Feoktistova, W. H. McDonald, I. McLeod, J. R. Yates III, K. L. Gould, et al. (2012)
Mol. Biol. Cell
23, 3348-3356
|Abstract »|Full Text »|PDF »
CHFR Protein Regulates Mitotic Checkpoint by Targeting PARP-1 Protein for Ubiquitination and Degradation.
L. Kashima, M. Idogawa, H. Mita, M. Shitashige, T. Yamada, K. Ogi, H. Suzuki, M. Toyota, H. Ariga, Y. Sasaki, et al. (2012)
J. Biol. Chem.
287, 12975-12984
|Abstract »|Full Text »|PDF »
The Auto-ubiquitylation of E3 Ubiquitin-protein Ligase Chfr at G2 Phase Is Required for Accumulation of Polo-like Kinase 1 and Mitotic Entry in Mammalian Cells.
J.-S. Kim, Y.-Y. Park, S.-Y. Park, H. Cho, D. Kang, and H. Cho (2011)
J. Biol. Chem.
286, 30615-30623
|Abstract »|Full Text »|PDF »
The Stil protein regulates centrosome integrity and mitosis through suppression of Chfr.
A. Castiel, M. M. Danieli, A. David, S. Moshkovitz, P. D. Aplan, I. R. Kirsch, M. Brandeis, A. Kramer, and S. Izraeli (2011)
J. Cell Sci.
124, 532-539
|Abstract »|Full Text »|PDF »
Structural Basis of Poly(ADP-ribose) Recognition by the Multizinc Binding Domain of Checkpoint with Forkhead-associated and RING Domains (CHFR).
J. Oberoi, M. W. Richards, S. Crumpler, N. Brown, J. Blagg, and R. Bayliss (2010)
J. Biol. Chem.
285, 39348-39358
|Abstract »|Full Text »|PDF »
Safeguarding Entry into Mitosis: the Antephase Checkpoint.
Molecular Distinctions between Aurora A and B: A Single Residue Change Transforms Aurora A into Correctly Localized and Functional Aurora B.
F. Hans, D. A. Skoufias, S. Dimitrov, and R. L. Margolis (2009)
Mol. Biol. Cell
20, 3491-3502
|Abstract »|Full Text »|PDF »
Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
A. G. Renner, C. Dos Santos, C. Recher, C. Bailly, L. Creancier, A. Kruczynski, B. Payrastre, and S. Manenti (2009)
Blood
114, 659-662
|Abstract »|Full Text »|PDF »
Functional Interaction between Chfr and Kif22 Controls Genomic Stability.
S. Maddika, S. M.-H. Sy, and J. Chen (2009)
J. Biol. Chem.
284, 12998-13003
|Abstract »|Full Text »|PDF »
Persistent FoxE3 Expression Blocks Cytoskeletal Remodeling and Organelle Degradation during Lens Fiber Differentiation.
H. Landgren, A. Blixt, and P. Carlsson (2008)
Invest. Ophthalmol. Vis. Sci.
49, 4269-4277
|Abstract »|Full Text »|PDF »
G2E3 Is a Dual Function Ubiquitin Ligase Required for Early Embryonic Development.
W. S. Brooks, E. S. Helton, S. Banerjee, M. Venable, L. Johnson, T. R. Schoeb, R. A. Kesterson, and D. F. Crawford (2008)
J. Biol. Chem.
283, 22304-22315
|Abstract »|Full Text »|PDF »
The Cech Symposium: A celebration of 25 years of ribozymes, 10 years of TERT, and 60 years of Tom.
Q. Vicens, M. A. Allen, S. D. Gilbert, B. Reznik, A. R. Gooding, and R. T. Batey (2008)
RNA
14, 397-403
|Abstract »|Full Text »|PDF »
Defective in Mitotic Arrest 1/Ring Finger 8 Is a Checkpoint Protein That Antagonizes the Human Mitotic Exit Network.
R. L. Tuttle, J. Bothos, M. K. Summers, F. C. Luca, and T. D. Halazonetis (2007)
Mol. Cancer Res.
5, 1304-1311
|Abstract »|Full Text »|PDF »
Altered Expression of the Early Mitotic Checkpoint Protein, CHFR, in Breast Cancers: Implications for Tumor Suppression.
L. M. Privette, M. E. Gonzalez, L. Ding, C. G. Kleer, and E. M. Petty (2007)
Cancer Res.
67, 6064-6074
|Abstract »|Full Text »|PDF »
The tumor suppressor CYLD regulates entry into mitosis.
F. Stegmeier, M. E. Sowa, G. Nalepa, S. P. Gygi, J. W. Harper, and S. J. Elledge (2007)
PNAS
104, 8869-8874
|Abstract »|Full Text »|PDF »
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy.
I. Perez de Castro, G. de Carcer, and M. Malumbres (2007)
Carcinogenesis
28, 899-912
|Abstract »|Full Text »|PDF »
Human T-Cell Leukemia Virus Oncoprotein Tax Represses Nuclear Receptor-Dependent Transcription by Targeting Coactivator TAX1BP1.
K.-T. Chin, A. C.S. Chun, Y.-P. Ching, K.-T. Jeang, and D.-Y. Jin (2007)
Cancer Res.
67, 1072-1081
|Abstract »|Full Text »|PDF »
Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer.
Hamartin, the tuberous sclerosis complex 1 gene product, interacts with polo-like kinase 1 in a phosphorylation-dependent manner.
A. Astrinidis, W. Senapedis, and E. P. Henske (2006)
Hum. Mol. Genet.
15, 287-297
|Abstract »|Full Text »|PDF »
Down-Regulation of DNA Topoisomerase II{alpha} Leads to Prolonged Cell Cycle Transit in G2 and Early M Phases and Increased Survival to Microtubule-Interacting Agents.
A. Skladanowski, M.-G. Come, M. Sabisz, A. E. Escargueil, and A. K. Larsen (2005)
Mol. Pharmacol.
68, 625-634
|Abstract »|Full Text »|PDF »
CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype.
J. C. Brandes, M. van Engeland, K. A.D. Wouters, M. P. Weijenberg, and J. G. Herman (2005)
Carcinogenesis
26, 1152-1156
|Abstract »|Full Text »|PDF »
Deficiency in SNM1 Abolishes an Early Mitotic Checkpoint Induced by Spindle Stress.
S. Akhter, C. T. Richie, J. M. Deng, E. Brey, X. Zhang, C. Patrick Jr., R. R. Behringer, and R. J. Legerski (2004)
Mol. Cell. Biol.
24, 10448-10455
|Abstract »|Full Text »|PDF »
Cdc123 and Checkpoint Forkhead Associated with RING Proteins Control the Cell Cycle by Controlling eIF2{gamma} Abundance.
P. Bieganowski, K. Shilinski, P. N. Tsichlis, and C. Brenner (2004)
J. Biol. Chem.
279, 44656-44666
|Abstract »|Full Text »|PDF »
Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells.
Functional Characterization of Dma1 and Dma2, the Budding Yeast Homologues of Schizosaccharomyces pombe Dma1 and Human Chfr.
R. Fraschini, D. Bilotta, G. Lucchini, and S. Piatti (2004)
Mol. Biol. Cell
15, 3796-3810
|Abstract »|Full Text »|PDF »
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer.
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff (2004)
Mol. Cancer Ther.
3, 641-646
|Abstract »|Full Text »|PDF »
Dysregulation of the Polo-Like Kinase Pathway in CD4+ T Cells Is Characteristic of Pathogenic Simian Immunodeficiency Virus Infection.
P. Bostik, G. L. Dodd, F. Villinger, A. E. Mayne, and A. A. Ansari (2004)
J. Virol.
78, 1464-1472
|Abstract »|Full Text »|PDF »
Epigenetic Inactivation of CHFR and Sensitivity to Microtubule Inhibitors in Gastric Cancer.
A. Satoh, M. Toyota, F. Itoh, Y. Sasaki, H. Suzuki, K. Ogi, T. Kikuchi, H. Mita, T. Yamashita, T. Kojima, et al. (2003)
Cancer Res.
63, 8606-8613
|Abstract »|Full Text »|PDF »
p190RhoGAP is cell cycle regulated and affects cytokinesis.
M. Toyota, Y. Sasaki, A. Satoh, K. Ogi, T. Kikuchi, H. Suzuki, H. Mita, N. Tanaka, F. Itoh, J.-P. J. Issa, et al. (2003)
PNAS
100, 7818-7823
|Abstract »|Full Text »|PDF »
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer.
P. G. Corn, M. K. Summers, F. Fogt, A. K. Virmani, A. F. Gazdar, T. D. Halazonetis, and W. S. El-Deiry (2003)
Carcinogenesis
24, 47-51
|Abstract »|Full Text »|PDF »